Melanoma News and Research

Latest Melanoma News and Research

Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients

Researchers with UCLA's Jonsson Comprehensive Cancer Center have found that melanoma patients whose cancers are caused by mutation of the BRAF gene become resistant to a promising targeted treatment through another genetic mutation or the overexpression of a cell surface protein, both driving survival of the cancer and accounting for relapse.

25 Nov 2010

Provectus reports progress in PV-10 program for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.

24 Nov 2010

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP biotherapy at the "Electrochemotherapy 1st International Users' Meeting"(Bologna, Italy, November 19-20, 2010).

23 Nov 2010

IsoRay to sell $2.25 million in common stock

IsoRay Inc. has entered a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 additional funding through two subsequent short term warrant tranches of 90 days and 180 days assuming an average exercise price of $1.40 and that all Series A and B warrants are exercised. Additional funding will occur if Series C or D warrants are exercised.

22 Nov 2010

Cascade reaffirms position on non-invasive detection of melanoma by SkinSpect device

Cascade Technologies, Corp. announced today that, in response to significant recent attention to the Food and Drug Administration (FDA) panel evaluation of Mela Sciences' MelaFind device, the company has received a number of inquiries about its similar instrument.

20 Nov 2010

Myrexis announces poster presentation on Azixa at Neuro-Oncology Scientific Meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced a poster presentation of its lead product candidate Azixa (verubulin, MPC-6827) at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day in Montreal, Canada.

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

CINJ experts to comment on importance of blood donation

Every two seconds, there is someone in the United States in need of blood. According to the American Red Cross, 65 percent of the American population is eligible to donate blood, but only five percent actually do. In New Jersey only two and a half percent of eligible donors will donate, while nine out of ten New Jersey residents will need blood at least once in their lives.

19 Nov 2010

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation.

19 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Researchers unveil novel oncogene associated with uveal melanoma

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer.

18 Nov 2010

New theoretical model could develop novel clinical decision making in cancer research

Schonfeld, a University of Illinois at Chicago professor of electrical and computer engineering, is studying gene expression and interactions in ways that are analogous to the workings of electrical or computer networks. He is project director and principal investigator of a four-year, $1.2 million National Institutes of Health grant.

18 Nov 2010

Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today presented posters on encouraging preclinical results for AEZS-129 and AEZS-132, two novel orally active compounds with anti-tumor effects.

17 Nov 2010

Study finds phenotypic plasticity among melanoma cells

University of Michigan researchers have determined that most types of melanoma cells can form malignant tumors, providing new evidence that the deadliest form of skin cancer does not conform to the increasingly popular cancer stem cell model.

17 Nov 2010

Dutch government awards Innovation Credit of EUR 1.3 million to InteRNA

InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, today announced that it was awarded an Innovation Credit of EUR 1.3 million from the Dutch government.

16 Nov 2010

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Affluent people face higher risk of melanoma

According to scientists at the Cancer Prevention Institute of California (CPIC), affluent people are at a much higher risk of melanoma than the rest of the population of whites in California.

10 Nov 2010

Melanoma News and Research

Latest Melanoma News and Research

Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients

Provectus reports progress in PV-10 program for metastatic melanoma

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

IsoRay to sell $2.25 million in common stock

Cascade reaffirms position on non-invasive detection of melanoma by SkinSpect device

Myrexis announces poster presentation on Azixa at Neuro-Oncology Scientific Meeting

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

DoD recommends funding for Synta's STA-9584 for prostate cancer study

CINJ experts to comment on importance of blood donation

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Researchers unveil novel oncogene associated with uveal melanoma

New theoretical model could develop novel clinical decision making in cancer research

Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium

Study finds phenotypic plasticity among melanoma cells

Dutch government awards Innovation Credit of EUR 1.3 million to InteRNA

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Affluent people face higher risk of melanoma

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Melanoma News and Research

Latest Melanoma News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in